Dosage Forms
Publication Brings Analytical Science to Cannabis Industry
April 03, 2018
A new scientific publication examines analytical processes for the emerging legal cannabis industry.
FDA Grants Priority Review to AstraZeneca’s Leukemia Biologic
April 03, 2018
The agency has accepted AstraZeneca’s biologics license application for an investigational leukemia drug candidate and granted it priority review.
Pfizer Transfers CAR-T Assets to Allogene
April 03, 2018
Pfizer transfers CAR-T assets to Allogene Therapeutics under a new alliance to further develop immuno-oncology therapeutics.
Optimizing Particle Engineering Methods for Inhalation Drug Products
April 02, 2018
Particle engineering using jet milling or spray drying can be used to obtain appropriate particle characteristics for inhalation drug products.
Multiple Views Deliver Complete Characterization of Protein Particles
April 02, 2018
Access to multiple analytical techniques is essential for fully characterizing complex protein formulations.
Modern Manufacturing Key to More Effective Vaccines
April 02, 2018
Accelerated development of new preventives raises challenges for efficient CMC evaluation and production.
Delivering High-Concentration Protein Formulations
April 02, 2018
The high viscosity of highly concentrated monoclonal antibody formulations not only presents processing and storage difficulties, but also formulation and delivery challenges.
Future Therapies Using Implanted Engineered Cells as Protein Factories
April 02, 2018
Researchers at MIT have discovered a new set of compounds that do not elicit a foreign body response when implanted. These biomaterials permit the development of a new category of treatment with the ability to deliver therapeutics either at a constant rate or under programmable conditions by using implantable cells as protein factories.
Celgene, bluebird bio Partner on CAR-T Therapy
March 29, 2018
The companies will co-develop and co-promote a CAR T cell therapy in the United States.
Novartis Gets Positive EMA Opinion on Biosimilar to J&J’s Remicade
March 29, 2018
Novartis’ Sandoz is seeking approval of its biosimilar referencing Johnson & Johnson’s Remicade (infliximab) for all of Remicade’s indications across gastroenterology, rheumatology, and dermatology.